All In Biotech

Drug Trial Radar · NCT04532749

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Last checked: Nov 20, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

212

Actual

Start

Sep 15, 2020

Primary completion

May 24, 2022

Study completion Jul 14, 2022

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Conditions

  • Depressive Disorder, Major

Interventions

  • SeltorexantDrug

    Participants will receive Seltorexant tablets.

  • PlaceboDrug

    Participants will receive matching placebo tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline (Day 1), Day 43

Locations

80 sites in 10 countries. Site status is shown where the registry gives one.

  • Altea Research Institute

    Phoenix, Arizona

  • Preferred Research Partners

    Little Rock, Arkansas

  • Behavioral Research Specialists LLC

    Glendale, California

  • Sun Valley Research Center

    Imperial, California

  • Alliance for Research

    Long Beach, California

  • Excell Research Inc

    Oceanside, California

  • California Neuroscience Research Medical Group, Inc.

    Sherman Oaks, California

  • Pharmax Research Clinic Inc

    Miami, Florida

  • Innova Clinical Trials

    Miami, Florida

  • Harmony Clinical Research Inc

    North Miami Beach, Florida

  • Medical Research Group of Central Florida

    Orange City, Florida

  • Synexus Research Orlando

    Orlando, Florida

  • Stedman Clinical Trials

    Tampa, Florida

  • Compass Research LLC-Bioclinica Research

    The Villages, Florida

  • Synexus Clinical Research US Inc

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Uptown Research Institute, LLC

    Chicago, Illinois

  • Phoenix Medical Research, Inc.

    Prairie Village, Kansas

  • Michigan Clinical Research Institute

    Ann Arbor, Michigan

  • Eastside Comprehensive Medical Services

    New York, New York

  • Community Research Management Associates, Inc.

    Cincinnati, Ohio

  • Patient Priority Clinical Sites LLC

    Cincinnati, Ohio

  • Intend Research

    Norman, Oklahoma

  • IPS Research Company

    Oklahoma City, Oklahoma

  • InSite Clinical Research LLC

    DeSoto, Texas

  • Pillar Clinical Research, LLC

    Richardson, Texas

  • Clínica Privada Banfield S.A

    Banfield, Argentina

  • STAT Research S A

    Buenos Aires, Argentina

  • NOVAIN Neurociencias Group

    Buenos Aires, Argentina

  • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales

    Buenos Aires, Argentina

  • CEN Consultorios Especializados en Neurociencias

    Córdoba, Argentina

  • Instituto Medico DAMIC

    Córdoba, Argentina

  • Sanatorio Prof. Leon S. Morra

    Córdoba, Argentina

  • INSA Instituto de Neurociencias San Agustín

    La Plata, Argentina

  • C I A P Centro de investigacion y Asistencia en Psiquiatria

    Rosario, Argentina

  • Clinica Mayo de UMCB

    San Miguel de Tucumán, Argentina

  • Psicomed Estudios Medicos

    Antofagasta, Chile

  • BioMedica Research Group

    Santiago, Chile

  • CeCim - Centro de Estudios Clinicos e Investigacion Medica

    Santiago, Chile

  • Hospital Dr Hernan Henriquez Aravena

    Temuco, Chile

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.